- Home
- MDGL vs CWAN Comparison
MDGL vs CWAN Comparison
Compare MDGL & CWAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- CWAN
- Stock Information
- Founded
- MDGL 2011
- CWAN 2004
- Country
- MDGL United States
- CWAN United States
- Employees
- MDGL N/A
- CWAN N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- CWAN Computer Software: Prepackaged Software
- Sector
- MDGL Health Care
- CWAN Technology
- Exchange
- MDGL Nasdaq
- CWAN Nasdaq
- Market Cap
- MDGL 6.8B
- CWAN 7.3B
- IPO Year
- MDGL N/A
- CWAN 2021
- Fundamental
- Price
- MDGL $319.93
- CWAN $22.75
- Analyst Decision
- MDGL Buy
- CWAN Buy
- Analyst Count
- MDGL 9
- CWAN 9
- Target Price
- MDGL $386.29
- CWAN $33.89
- AVG Volume (30 Days)
- MDGL 333.2K
- CWAN 2.5M
- Earning Date
- MDGL 05-01-2025
- CWAN 04-30-2025
- Dividend Yield
- MDGL N/A
- CWAN N/A
- EPS Growth
- MDGL N/A
- CWAN N/A
- EPS
- MDGL N/A
- CWAN 1.68
- Revenue
- MDGL $180,133,000.00
- CWAN $451,803,000.00
- Revenue This Year
- MDGL $230.69
- CWAN $21.92
- Revenue Next Year
- MDGL $74.76
- CWAN $19.11
- P/E Ratio
- MDGL N/A
- CWAN $13.53
- Revenue Growth
- MDGL N/A
- CWAN 22.72
- 52 Week Low
- MDGL $189.00
- CWAN $15.62
- 52 Week High
- MDGL $377.46
- CWAN $35.71
- Technical
- Relative Strength Index (RSI)
- MDGL 50.76
- CWAN 39.67
- Support Level
- MDGL $276.20
- CWAN $21.13
- Resistance Level
- MDGL $330.64
- CWAN $23.25
- Average True Range (ATR)
- MDGL 20.79
- CWAN 1.22
- MACD
- MDGL 0.06
- CWAN -0.00
- Stochastic Oscillator
- MDGL 76.56
- CWAN 49.02
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About CWAN Clearwater Analytics Holdings Inc.
Clearwater Analytics Holdings Inc provides a SaaS solution for automated investment data aggregation, reconciliation, accounting and reporting services to insurers, investment managers, corporations, institutional investors and government entities. It earns revenue from providing access to its SaaS platform to customers, services that support the implementation on the SaaS platform, selling perpetual and term-based software licenses and providing maintenance and support and professional services under contracts with customers. The majority of the revenue is earned in the United States.